Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007201
Chunk: 3

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 3
---
 the July 2024 Private
Placement, (2) 2,131,880,000 Ordinary Shares represented by 213,188 Depositary Shares, issuable upon the exercise of Series K warrants,
or Series K Warrants, issued in the July 2024 Private Placement, and (3) 85,250,000 Ordinary Shares represented by 8,525 Depositary Shares,
issuable upon the exercise of placement agent warrants, or the July 2024 Placement Agent Warrants, issued in the July 2024 Private Placement.

The selling shareholders are
identified in the table commencing on page 65. Each Depositary Share represents 10,000 Ordinary Shares. No Depositary Shares are being
registered hereunder for sale by us. We will not receive any proceeds from the sale of the Depositary Shares by the selling shareholders.
All net proceeds from the sale of the Ordinary Shares represented by Depositary Shares covered by this prospectus will go to the selling
shareholders. However, we may receive proceeds from any exercise of warrants held by selling shareholders. See “Use of Proceeds.”

The selling shareholders may
sell all or a portion of the Ordinary Shares represented by Depositary Shares from time to time in market transactions through any market
on which our Depositary Shares are then traded, in negotiated transactions or otherwise, and at prices and on terms that will be determined
by the then prevailing market price or at negotiated prices directly or through a broker or brokers, who may act as agent or as principal
or by a combination of such methods of sale. See “Plan of Distribution.”

Our Depositary Shares are
listed on the NASDAQ Capital Market under the symbol “BDRX.” The last reported closing price of our Depositary Shares on the
NASDAQ Capital Market on May 7, 2025 was $1.38.

Investing in our securities involves risks. See “Risk Factors” beginning on page 9 of this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus is , 2025</div>

<div align='center'>TABLE OF CONTENTS</div>

|                                                      | Page |
| ABOUT THIS PROSPECTUS                                |    1 |
| PRESENTATION OF FINANCIAL